Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.55 |
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | PRKACG | P22612 | 1/20 | 0.44 |
| ▸ | PRKACB | P22694 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 2/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495932 | 0.83 | HPGDS (0.64) | HPGDSGRM5DGAT1GABRA5ROCK2 | |
| SCHEMBL16495384 | 0.81 | HPGDS (0.58) | HPGDSGRM5DGAT1CNR2GABRA5 | |
| SCHEMBL16495759 | 0.81 | HPGDS (0.53) | HPGDSGRM5DGAT1CNR2GABRA5 | |
| SCHEMBL16495506 | 0.80 | HPGDS (0.55) | HPGDSROCK2PRKACAAKT1PRKG1 | |
| SCHEMBL16495644 | 0.79 | HPGDS (0.51) | HPGDSGRM5DGAT1CNR1CNR2 | |
| SCHEMBL6929730 | 0.79 | GRM5 (0.78) | GRM5GABRA5 | |
| SCHEMBL16495367 | 0.79 | HPGDS (0.56) | HPGDSGABRA5PRKACGBAZ2BWNT3A | |
| SCHEMBL16495713 | 0.79 | HPGDS (0.56) | HPGDSDGAT1GABRA5ROCK2PRKACA | |
| SCHEMBL16495568 | 0.78 | HPGDS (0.60) | HPGDSGRM5DGAT1GABRA5ROCK2 | |
| SCHEMBL16495991 | 0.78 | HPGDS (0.57) | HPGDSGRM5GABRA5BAZ2BWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885GRM5 3155/4885DGAT1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.